Voiant Acquires Voxeleron to Boost AI in Ophthalmic Research

Voiant has announced the acquisition of Voxeleron, a company known for its AI-driven ophthalmic image analysis technology. This acquisition is a strategic move to enhance Voiant's capabilities in clinical trial imaging solutions, particularly in the field of ophthalmology.
The integration of Voxeleron's advanced AI technology with Voiant's clinical trial expertise is expected to drive innovation in ophthalmic research. The combined platform will offer enhanced capabilities in retinal and corneal imaging, providing deeper clinical insights and improving data accuracy. This development aims to accelerate the creation of innovative treatments for eye diseases, ultimately benefiting patients.
Jim Primerano, CEO of Voiant, emphasized that this acquisition represents a significant leap forward for the company, setting new standards in ophthalmic clinical research. Voxeleron's co-founders, Jonathan Oakley and Daniel Russakoff, expressed excitement about the collaboration, highlighting the potential to change the paradigm in ophthalmology and improve patient outcomes.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Funding
More from: Life Sciences
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 State of Data Security Report: Quantifying AI’s Impact on Data Risk
The 2025 State of Data Security Report by Varonis analyzes the impact of AI on data security across 1,000 IT environments. It highlights critical vulnerabilities such as exposed sensitive cloud data, ghost users, and unsanctioned AI applications. The report emphasizes the need for robust data governance and security measures to mitigate AI-related risks.
Read more